Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture.

[1]  D. Barlow.  HRT and the risk of deep vein thrombosis , 1997, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[3]  R. Sekel,et al.  Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism , 1998, The Medical journal of Australia.

[4]  L. Nachtigall,et al.  Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. , 1979 .

[5]  J. Glowacki,et al.  Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. , 1999, JAMA.

[6]  J. Kanis.  Osteoporosis and osteopenia , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  I. Shinkai,et al.  New drugs--reports of new drugs recently approved by the FDA. Alendronate. , 1996, Bioorganic & Medicinal Chemistry.

[8]  M. Prostko.  Meta-analysis of prevention of nonvertebral fractures by alendronate. , 1997, JAMA.

[9]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[10]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[11]  E. Barrett-Connor,et al.  Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.

[12]  M. Erlandsen,et al.  Occurrence and incidence of the second hip fracture. , 1993, Clinical orthopaedics and related research.

[13]  L. Melton,et al.  Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  S. Cummings,et al.  Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. , 1989, Archives of internal medicine.

[15]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[16]  R. Recker,et al.  Correcting calcium nutritional deficiency prevents spine fractures in elderly women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[18]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[19]  A Hofman,et al.  Bone density and risk of hip fracture in men and women: cross sectional analysis , 1997, BMJ.

[20]  François Duboeuf,et al.  Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women , 1992 .

[21]  C. Wilson,et al.  Observations on nursing home residents with a history of hip fracture. , 1995, The American journal of the medical sciences.

[22]  D. Grady,et al.  Postmenopausal hormone therapy increases risk of deep vein thrombosis and pulmonary embolism , 1998 .